Standridge John B
Department of Family Medicine, University of Tennessee Health Science Center College of Medicine, Chattanooga, Tennessee 37403, USA.
Curr Alzheimer Res. 2006 Apr;3(2):95-108. doi: 10.2174/156720506776383068.
Rigorous scientific research has identified multiple interactive mechanisms that parallel and are likely causative of the development of Alzheimer's disease (AD). Causative mechanisms include genomics, the creation of amyloid beta (Abeta), factors inhibiting the Abeta removal process, the transformation of Abeta to its toxic forms (various forms of Abeta aggregation), and lastly the oxidative, inflammatory, and other effects of toxic Abeta. Fibrillar beta-amyloid peptide, a major component of senile plaques in AD brain, is known to induce microglial-mediated neurotoxicity under certain conditions, but some recent studies support the notion that Abeta oligomers are the primary neurotoxins. Abeta-42 oligomers that are soluble and highly neurotoxic, referred to as Abeta-derived diffusible ligands (ADDLs), assemble under conditions that block fibril formation. These oligomers bind to dendrite surfaces in small clusters with ligand-like specificity and are capable of destroying hippocampal neurons at nanomolar concentrations. Evidence is presented that AD is triggered by these soluble, neurotoxic assemblies of Abeta rather than the late stage pathology landmarks of amyloid plaques and tangles. The premise is that AD symptoms stem from aberrant nerve cell signaling and synaptic failure rather than nerve cell death, which nevertheless follows and exacerbates the initial pathologies of AD. The defective clearance of amyloid leads to amyloid angiopathy that in turn perpetuates hypoperfusion that affects formation as well as absorption of CSF thereby altering clearance of amyloid and promoting vascular and parenchymal deposition[1]. Hypoperfusion, the defective clearance of amyloid, and resultant increase in amyloid deposition thus represent a vicious cycle. Chronic vascular hypoperfusion-induced mitochondrial failure results in oxidative damage, which drives caspase 3-mediated Abeta peptide secretion and enhances amyloidogenic APP processing. Intracellular Abeta accumulation in turn promotes a significant oxidative and inflammatory mechanism that generates a vicious cycle of Abeta generation and oxidation, each accelerating the other. Abeta activates astrocytes that add to the oxidative imbalance, upregulate the expression of APP via TGF-beta, and are capable of expressing BACE1. Each of these 3 actions accelerates the larger cycle of cholinergic neuron destruction. As oxidative stress induces lesions of cholinergic nuclei producing a reduction in cholinergic neurotransmission, a subsequent increase in cortical APP involving PKCepsilon leads to accelerated amyloidogenic APP metabolism. The linkage of cholinergic activation and APP metabolism completes an additional feedback loop wherein the damage wrought by Abeta accelerates further Abeta production. A comprehensive vision of the neuropathophysiologic mechanisms that result in AD reveals several vicious cycles within a larger vicious cycle, that is to say, a number of interactive systems that each, once set in motion, amplify their own processes, thus accelerating the development of AD.
严谨的科学研究已确定了多种相互作用机制,这些机制与阿尔茨海默病(AD)的发展并行且可能是其病因。致病机制包括基因组学、β-淀粉样蛋白(Aβ)的产生、抑制Aβ清除过程的因素、Aβ向其毒性形式的转化(Aβ的各种聚集形式),以及最后有毒Aβ的氧化、炎症和其他作用。纤维状β-淀粉样肽是AD大脑中老年斑的主要成分,已知在某些条件下会诱导小胶质细胞介导的神经毒性,但最近的一些研究支持Aβ寡聚体是主要神经毒素的观点。可溶性且具有高度神经毒性的Aβ-42寡聚体,称为Aβ衍生的可扩散配体(ADDLs),在阻止纤维形成的条件下组装。这些寡聚体以类似配体的特异性以小簇形式结合到树突表面,并且能够在纳摩尔浓度下破坏海马神经元。有证据表明,AD是由这些可溶性、神经毒性的Aβ组装体引发的,而不是淀粉样斑块和缠结的晚期病理标志。前提是AD症状源于异常的神经细胞信号传导和突触功能障碍,而不是神经细胞死亡,尽管神经细胞死亡会随之发生并加剧AD的初始病理过程。淀粉样蛋白清除缺陷导致淀粉样血管病,进而使灌注不足持续存在,这会影响脑脊液的形成和吸收,从而改变淀粉样蛋白的清除并促进血管和实质沉积[1]。灌注不足、淀粉样蛋白清除缺陷以及由此导致的淀粉样蛋白沉积增加因此代表了一个恶性循环。慢性血管灌注不足诱导的线粒体功能衰竭导致氧化损伤,这驱动半胱天冬酶3介导的Aβ肽分泌并增强淀粉样前体蛋白(APP)的加工。细胞内Aβ积累反过来促进显著的氧化和炎症机制,产生Aβ生成和氧化的恶性循环,二者相互加速。Aβ激活星形胶质细胞,这会加剧氧化失衡,通过转化生长因子-β上调APP的表达,并能够表达β-分泌酶1(BACE1)。这三种作用中的每一种都会加速胆碱能神经元破坏的更大循环。由于氧化应激诱导胆碱能核损伤,导致胆碱能神经传递减少,随后涉及蛋白激酶Cε(PKCε)的皮质APP增加会导致淀粉样前体蛋白代谢加速。胆碱能激活与APP代谢的联系完成了另一个反馈回路,其中Aβ造成的损伤会加速更多Aβ的产生。对导致AD的神经病理生理机制的全面认识揭示了一个更大恶性循环中的几个恶性循环,也就是说,一些相互作用的系统,一旦启动,每个系统都会放大自身过程,从而加速AD的发展。